ZYUS Life Sciences
Manufacturing · Canada · 51-200 Employees
View Company Info for Free
Overview
Headquarters
204-407 Downey Rd, Saskatoon, Saskatchew...Phone Number
(888) 651-9987Website
www.zyus.comRevenue
<$5 MillionStock Symbol
ZYUSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About ZYUS Life Sciences
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musculoskeletal injuries, arthritis, and cancer. It operates in Canada, the United States, Australia, and the European Union. ZYUS Life Sciences Corporation was founded in 2018 and is headquartered in Saskatoon, Canada.Explore more
ZYUS Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ZYUS Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if ZYUS Life Sciences had a recent Job posting/layoffs
Check out if ZYUS Life Sciences is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at ZYUS Life Sciences
Product Launch: Get notified when ZYUS Life Sciences launches new products
Funding: Get notified immidiatlly once ZYUS Life Sciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on ZYUS Life Sciences recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check if ZYUS Life Sciences has recently received funding, and reach out quickly before it becomes old news!
ZYUS Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined ZYUS Life Sciences as Masked Content
Find 2 more new buyers
Compare Similar Companies to ZYUS Life Sciences
Compare insights from companies similar to ZYUS Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ZYUS Life Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
ZYUS Life Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about ZYUS Life Sciences.
ZYUS Life Sciences financials insights
Gather financial insights about ZYUS Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Private Equity
$73K
2026
Debt
$106K
ZYUS Life Sciences Tech Stack
A closer look at the technologies used by ZYUS Life Sciences
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
ZYUS Life Sciences News & Media
ZYUS Life Sciences Corporation Announces Closing of Sixth Tranche of Secured Loan Financing
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed a sixth tranche (the "Sixth Tranche") of a secured loan financing (the "Secured Loan") on July 21, 2026 with certain lenders (the "Lenders"), including an insider of the Company, for grosZYUS Life Sciences Corporation Announces Closing of Fifth Tranche of Secured Loan Financing
/CNW/ - ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of...ZYUS Life Sciences Corporation Announces Closing of Fourth Tranche of Secured Loan Financing
Detailed price information for Zyus Life Sciences Corporation (ZYUS-X) from The Globe and Mail including charting and trades.ZYUS Life Sciences Corporation Announces Closing of Third Tranche of Secured Loan Financing
ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, is pleased to announce that its wholly-owned subsidiary, ZYUS Life Sciences Inc. ("ZYUS Inc."), has closed a third tranche (the "Third Tranche") of a secured loan financing (the "Secured Loan") on June 17, 2026 with certain lenders (the "Lenders"), including certain insiders of the Company, fo
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding ZYUS Life Sciences
Sign Up For FreeTo access detailed company insights
ZYUS Life Sciences Corporation manufactures and distributes cannabinoid-based therapeutics and product candidates for medical and adult recreational. The company offers Trichomylin, a softgel capsules with fixed dose combination of cannabinoids formulated that is phase 2a clinical trial for the treatment of chronic pain in adults caused due to musc... Read More
